Physician
Louisiana Women's Healthcare Associates LLC.
Louisiana Women's Healthcare Associates LLC. was paid $10.96M by Medicaid between May 2019 and Dec 2024, across 61 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 34% of everything it billed.
33Billing provider infoLOUISIANA WOMEN'S HEALTHCARE ASSOCIATES LLC.
BATON ROUGE, LA 70817
BATON ROUGE, LA 70817
33aNPI1598834269assigned 11/07/2006
33bProvider typeObstetrics & Gynecology Physician
28Total paid$10.96M
24GClaims260,427
24DCodes billed61
24AFirst – last monthMay 2019 – Dec 2024
Compared with peers
Next to other Obstetrics & Gynecology Physician providers in Louisiana
Rank by total paid#1 of 126
Median peer was paid$155K
This provider vs. median71×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 58 | $2K | |
| 2021 | 13,583 | $717K | |
| 2022 | 51,337 | $2.60M | |
| 2023 | 93,432 | $3.86M | |
| 2024incomplete | 102,017 | $3.78M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 34% | 74,161 | 49,515 | $3.68M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 6.6% | 12,104 | 10,176 | $721K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.6% | 7,352 | 5,363 | $509K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.6% | 14,003 | 12,339 | $505K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.6% | 14,055 | 12,382 | $505K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.9% | 13,170 | 9,925 | $430K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 3.9% | 15,109 | 13,244 | $426K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 3.8% | 6,666 | 5,631 | $422K |
| 59409 | Vaginal delivery only (with or without episiotomy and/or forceps) | 3.4% | 610 | 592 | $375K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 3.2% | 4,062 | 3,861 | $353K |
| 59430 | 2.9% | 3,055 | 2,750 | $319K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 2.8% | 4,272 | 4,105 | $310K |
49 more codes
| 76819 | Fetal biophysical profile; without non-stress testing | 2.7% | 4,729 | $296K |
| 81513 | 2.2% | 2,650 | $239K | |
| 99204 | Doctor's office visit, new patient (more involved) | 2.2% | 2,382 | $237K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 2.1% | 9,911 | $230K |
| 0502F | 2.0% | 7,514 | $215K | |
| 87481 | 1.5% | 7,184 | $167K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 1.2% | 1,909 | $127K |
| 59514 | <1% | 261 | $107K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,997 | $97K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,501 | $95K |
| 76830 | Ultrasound, transvaginal | <1% | 1,226 | $80K |
| 86592 | <1% | 10,143 | $66K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 9,189 | $63K |
| 99205 | Prolong outpt/office vis | <1% | 488 | $58K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 890 | $52K |
| 87340 | <1% | 4,016 | $50K | |
| 99385 | <1% | 550 | $47K | |
| 87653 | <1% | 1,660 | $46K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,900 | $27K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 392 | $14K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 277 | $12K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 119 | $10K |
| 86803 | <1% | 728 | $10K | |
| 85660 | <1% | 1,593 | $8K | |
| 82950 | <1% | 1,576 | $7K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 75 | $6K |
| 81514 | <1% | 105 | $6K | |
| 76801 | <1% | 69 | $5K | |
| 90715 | <1% | 130 | $4K | |
| 54150 | <1% | 24 | $3K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 94 | $3K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 248 | $3K |
| 0503F | <1% | 208 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 400 | $2K |
| 81025 | <1% | 370 | $2K | |
| 81003 | <1% | 570 | $1K | |
| 99386 | <1% | 12 | $1K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 17 | $1K |
| 0500F | <1% | 152 | $930.00 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 74 | $918.42 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 72 | $703.62 |
| 81001 | <1% | 230 | $562.68 | |
| 84439 | <1% | 58 | $402.56 | |
| 87511 | <1% | 30 | $389.49 | |
| 90674 | <1% | 13 | $365.28 | |
| 90661 | <1% | 32 | $184.25 | |
| 82951 | <1% | 12 | $155.76 | |
| 80053 | Comprehensive metabolic panel | <1% | 16 | $149.43 |
| 82952 | <1% | 12 | $47.52 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSANGARI, KIM (CHIEF EXECUTIVE OFFICER)